Therefore, recommendations for breast cancer screening or treatments will remain unchanged for most women. The study, led by investigators from the National Cancer Institute (NCI), part of the National Institutes of Health, and the Harvard School of Public Health (HSPH) appears in the March 18, 2010 issue of the New England Journal of Medicine.
“Unlike the situation for women with a strong family history of breast cancer, in which a search for rare disease-causing variants may be useful, for women without a strong family history breast cancer risk prediction based on common risk variants is currently of marginal utility,” said lead author David Hunter, Dean for Academic Affairs and Vincent L. Gregory Professor in Cancer Prevention at HSPH.
Findings from genome-wide association studies have identified multiple genetic variants associated with breast cancer. To test whether this information would increase the value of breast cancer risk models, the researchers assembled information on traditional risk factors and 10 common genetic variants associated with breast cancer in 5,590 breast cancer patients and 5,998 women without cancer, 50 to 79 years of age, from four cohort studies and one case control study.
The investigators examined the predictive accuracy of the commonly used Gail model, which uses information on a woman’s own personal medical and reproductive history, as well as the history of breast cancer among her first-degree relatives (mother, sisters and children) to estimate her risk of developing invasive breast cancer within the next five years, or over her lifetime. The investigators then tested the accuracy of a model using the newly discovered genetic factors and found that it was as good as the Gail model alone. An inclusive model, using both genetic and Gail risk factors, performed only slightly better than either model alone.
The authors emphasized that the genome-wide association studies represent an early stage in understanding the inherited components of breast cancer risk.
View the National Cancer Institute press release: http://www.cancer.gov/newscenter/pressreleases/GeneticVariantsBreast
For more information:
Harvard School of Public Health ( http://www.hsph.harvard.edu ) is dedicated to advancing the public’s health through learning, discovery, and communication. More than 400 faculty members are engaged in teaching and training the 1,000-plus student body in a broad spectrum of disciplines crucial to the health and well being of individuals and populations around the world. Programs and projects range from the molecular biology of AIDS vaccines to the epidemiology of cancer; from risk analysis to violence prevention; from maternal and children’s health to quality of care measurement; from health care management to international health and human rights. For more information on the school visit: http://www.hsph.harvard.edu
NCI leads the National Cancer Program and the NIH effort to dramatically reduce the burden of cancer and improve the lives of cancer patients and their families, through research into prevention and cancer biology, the development of new interventions, and the training and mentoring of new researchers. For more information about cancer, please visit the NCI Web site at http://www.cancer.gov or call NCI’s Cancer Information Service at 1-800-4-CANCER (1-800-422-6237).
The National Institutes of Health (NIH)—The Nation’s Medical Research Agency—includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
To learn more about NCI’s Genome-Wide Association Studies, visit: http://www.grants.nih.gov/grants/gwas/